These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 14647069)

  • 1. Viral kinetics and hepatitis C.
    Lake-Bakaar G; Frost SD
    Hepatology; 2003 Dec; 38(6):1588; author reply 1588-1590. PubMed ID: 14647069
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
    Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
    Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on hepatitis. Baseline HCV VL, CD4 percentage predict HCV treatment response.
    Highleyman L
    IAPAC Mon; 2006 Oct; 12(10):375-6. PubMed ID: 17390500
    [No Abstract]   [Full Text] [Related]  

  • 4. HCV findings presented at EASL: long-term follow-up and the criteria of a cure.
    Lang L
    Gastroenterology; 2007 Jun; 132(7):2282-3. PubMed ID: 17570197
    [No Abstract]   [Full Text] [Related]  

  • 5. Delaying HCV treatment in HIV-positive patients.
    Carter M
    IAPAC Mon; 2005 May; 11(5):147. PubMed ID: 16201045
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

  • 8. High rate of infection with hepatitis C virus genotype 4 in a district of galicia, Spain.
    Martinez SM; Delgado MB; Castroagudín JF; Aguilera A
    J Clin Microbiol; 2005 Oct; 43(10):5403-4. PubMed ID: 16208032
    [No Abstract]   [Full Text] [Related]  

  • 9. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients.
    Liu CJ; Chen PJ; Lai MY; Kao JH; Jeng YM; Chen DS
    Hepatology; 2003 Mar; 37(3):568-76. PubMed ID: 12601355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa.
    Fontaine H; Chaix ML; Lagneau JL; Bréchot C; Pol S
    Lancet; 2000 Jul; 356(9223):41. PubMed ID: 10892765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.
    Pugnale P; Herrmann E; Neumann AU; Pawlotsky JM; Schalm SW; Ferrari C; Homburger Y; Zeuzem S; Negro F;
    J Hepatol; 2008 Jun; 48(6):932-8. PubMed ID: 18433918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?
    Hoefs JC; Morgan TR
    Hepatology; 2007 Dec; 46(6):1671-4. PubMed ID: 18046713
    [No Abstract]   [Full Text] [Related]  

  • 13. Interferon for hepatitis C patients with psychiatric disorders.
    Rifai MA; Bozorg B; Rosenstein DL
    Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol].
    Pivert A; Payan C; Lunel F;
    Pathol Biol (Paris); 2004 Nov; 52(9):522-8. PubMed ID: 15531116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two options for hepatitis C treatment.
    Pa Med; 1999 Apr; 102(4):22-3. PubMed ID: 10230275
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of hepatitis C.
    Sjogren MH
    Gastroenterology; 2006 Jul; 131(1):332; author reply 332-3. PubMed ID: 16831622
    [No Abstract]   [Full Text] [Related]  

  • 17. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 18. [Recurrence after customary hepatitis C therapy. Those patients are now treatable, too].
    MMW Fortschr Med; 2003 Feb; 145(9):55. PubMed ID: 12666534
    [No Abstract]   [Full Text] [Related]  

  • 19. [Primer treatment of acute and chronic hepatitis C].
    Daruich J; Fainboim H; Frider B
    Acta Gastroenterol Latinoam; 2006 Jun; 36 Suppl 1():S52-6; discussion S74-82. PubMed ID: 16862862
    [No Abstract]   [Full Text] [Related]  

  • 20. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.